This study is accepting new patients by invitation only
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
Summary
- Eligibility
- for people ages 18-80 (full criteria)
- Location
- at La Jolla, California and other locations
- Dates
- study startedestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients by invitation only
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AbbVie
- Links
- This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
- ID
- NCT03105102
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated